Brief: Jiangsu Recbio Technology Updates On Study Of COVID-19 Vaccine Recov In Philippines
14/12/2022 08:30
Dec 14 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* UPDATES ON STUDY OF RECOMBINANT TWO- COMPONENT COVID-19
VACCINE
RECOV IN PHILIPPINES
* POSITIVE RESULTS ACHIEVED FOR SEQUENTIAL BOOSTER
VACCINATION
PHASE II STUDY
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares